What is BTLA-HVEM in tumor immunity? What is BTLA-HVEM in tumor immunity? Preface Immunotherapy has changed the current...
Immunotherapy
Immunotherapy should not for first-line treatment of some cancer patients Immunotherapy should not for first-line treatment of some cancer...
How many Immunotherapies for advanced hepatocellular carcinoma? How many Immunotherapies for advanced hepatocellular carcinoma? Hepatocellular carcinoma is the...
Immunotherapy for small cell lung cancer: PD-1 vs PD-L1 Immunotherapy for small cell lung cancer: PD-1 vs PD-L1. In recent...
Physical immune checkpoints improve the effectiveness of tumor immunotherapy? Physical immune checkpoints improve the effectiveness of tumor immunotherapy? ...
B cells and CD4+ T cells join forces to activate killer T cells B cells and CD4+ T cells...
Cell: Continuous antigen stimulation can lead to CAR-T exhaustion Cell: Continuous antigen stimulation can lead to CAR-T exhaustion. ...
What is the workflow of TCR-T cell therapy for tumor treatment? What is the workflow of TCR-T cell therapy...
The mechanism of anti-PD-1 immunotherapy in lung cancer The mechanism of anti-PD-1 immunotherapy in lung cancer. On December 23,...
Cell: Necessary to overcome the dysfunction of CAR T cell therapy first Cell: Necessary to overcome the dysfunction of...
CAR-NK therapy for cancer immunotherapy CAR-NK therapy for cancer immunotherapy. Introduce So far, the clinical application of CAR...
Current status and challenges of immunotherapy for colorectal cancer Current status and challenges of immunotherapy for colorectal cancer. Preface...
How NK cells recognize and kill tumor? How NK cells recognize and kill tumor? Brief Introduction: Natural killer...
Oncolytic virus in the frontier of tumor immunotherapy Oncolytic virus in the frontier of tumor immunotherapy. Preface The development of...
Frontiers of Nanotechnology in Tumor Immunotherapy Frontiers of Nanotechnology in Tumor Immunotherapy. Preface At present, cancer is still...
New immunotherapy for lung cancer reduces disease progression by 38%. First-line treatment of lung cancer TIGIT antibody immune combination...
How to interpret the development of tumor immunity from the therapeutic field? How to interpret the development of tumor...
CD47 Targeting Double Antibody in Tumor Immunotherapy CD47 Targeting Double Antibody in Tumor Immunotherapy Preface So far, compared...
Preclinical study of Meso CAR-T for the treatment of solid tumors Preclinical study of Meso CAR-T for the treatment...
Research and clinical progress of RNA therapy Research and clinical progress of RNA therapy. Many RNA-based therapies involving siRNA,...
Why is the durability of CAR-T cell therapy limited? Why is the durability of CAR-T cell therapy limited? What...
Lancet Oncology: The different time of immunotherapy medication may cause the death risk double Lancet Oncology: The different time...
JACC: What are the hidden worries about CAR-T cell therapy? JACC: What are the hidden worries about CAR-T cell...
Multiple gene editing to construct a new generation of CAR-NK Multiple gene editing to construct a new generation of...
The latest paper from the father of CAR-T: Discovering new targets….. The latest paper from the father of CAR-T:...
What are the advantages of CAR-NK cell immunotherapy? What are the advantages of CAR-NK cell immunotherapy? Because NK...
How does autophagy play a role in tumor immunity and treatment? How does autophagy play a role in tumor immunity...
FT596: CAR-NK for the treatment of B cell malignant tumors FT596: CAR-NK for the treatment of B cell malignant...
A breakthrough new strategy for tumor immune cell therapy A breakthrough new strategy for tumor immune cell therapy. ...
Tumor Infiltrating Lymphocytes ( TILs ) in tumor immunotherapy Tumor Infiltrating Lymphocytes ( TILs ) in tumor immunotherapy. Preface Adoptive...
